Immunosuppression Reduces Lung Injury Caused by Mycoplasma Pneumoniae Infection

Overview

Journal Sci Rep

Specialty Science

Date 2019 May 11

PMID 31073201

Citations 18

Authors

Shuang Shi

Xiuqing Zhang

Yao Zhou

Heng Tang

Deyu Zhao

Feng Liu

Affiliations

Soon will be listed here.

Abstract

The underlying mechanisms of Mycoplasma pneumoniae pneumonia (MPP) pathogenesis are not clearly understood. This study aimed to investigate the correlation between immune response and lung injury in MPP. The clinical characteristics of MPP were compared between patients treated with and without immunosuppressive chemotherapy, and demographic, clinical, and laboratory data were compared between patients with severe and mild MPP. To determine the effect of immune response on lung lesions, mouse MPP and immunosuppression models were established by intranasal inoculation of M129 and intraperitoneal injection of cyclophosphamide, respectively. Myeloperoxidase and oxidant-antioxidant enzyme activities were evaluated for mechanism studies. The immunosuppressant group had a lower incidence of MPP and fewer cases of severe MPP than the non-immunosuppressant group. The severe MPP group had a greater incidence of severe immune disorders than the mild MPP group. Relative to immunosuppressed mice, wild mice exhibited more severe inflammatory infiltration and lung injury as well as a significant increase in myeloperoxidase and malondialdehyde levels and a decrease in superoxide dismutase level after MP infection. In conclusion, immunological responses likely play a vital role in MPP pathogenesis. Lung injury occurring after MP infection-which might be caused by oxidant-antioxidant imbalance-can be reduced by immunosuppression.

Citing Articles

Risk association model for atelectasis complication in pneumonia patients following standardized treatment.

Xu M, Fan M, Wang H, Qian J, Jiang Y, Zhu Y Front Pediatr. 2024; 12:1422074.

PMID: 39670190 PMC: 11634606. DOI: 10.3389/fped.2024.1422074.

Enhanced insights into the neutrophil-driven immune mechanisms during infection.

Fan L, Xu N, Guo Y, Li L Heliyon. 2024; 10(21):e38950.

PMID: 39524902 PMC: 11550053. DOI: 10.1016/j.heliyon.2024.e38950.

Single-cell transcriptome atlas revealed bronchoalveolar immune features related to disease severity in pediatric pneumonia.

Shen X, Jin Z, Chen X, Wang Z, Yi L, Ou Y MedComm (2020). 2024; 5(10):e748.

PMID: 39399649 PMC: 11471001. DOI: 10.1002/mco2.748.

Evaluating the role of interleukin-2 and interleukin-12 in pediatric patients with concurrent and Epstein-Barr virus infections.

Hao Y World J Clin Cases. 2024; 12(23):5346-5353.

PMID: 39156096 PMC: 11238690. DOI: 10.12998/wjcc.v12.i23.5346.

Association between infection, high‑density lipoprotein metabolism and cardiovascular health (Review).

Shen T, Li Y, Liu T, Lian Y, Kong L Biomed Rep. 2024; 20(3):39.

PMID: 38357242 PMC: 10865299. DOI: 10.3892/br.2024.1729.

References

Saraya T, Kurai D, Nakagaki K, Sasaki Y, Niwa S, Tsukagoshi H . Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications. Front Microbiol. 2014; 5:410. PMC: 4127663. DOI: 10.3389/fmicb.2014.00410. View

Sousa D, Justo I, Dominguez A, Manzur A, Izquierdo C, Ruiz L . Community-acquired pneumonia in immunocompromised older patients: incidence, causative organisms and outcome. Clin Microbiol Infect. 2012; 19(2):187-92. DOI: 10.1111/j.1469-0691.2012.03765.x. View

Nilsson A, Bjorkman P, Welinder-Olsson C, Widell A, Persson K . Clinical severity of Mycoplasma pneumoniae (MP) infection is associated with bacterial load in oropharyngeal secretions but not with MP genotype. BMC Infect Dis. 2010; 10:39. PMC: 2837002. DOI: 10.1186/1471-2334-10-39. View

Camp J, Jonsson C . A Role for Neutrophils in Viral Respiratory Disease. Front Immunol. 2017; 8:550. PMC: 5427094. DOI: 10.3389/fimmu.2017.00550. View

Shimizu T, Kida Y, Kuwano K . Cytoadherence-dependent induction of inflammatory responses by Mycoplasma pneumoniae. Immunology. 2011; 133(1):51-61. PMC: 3088967. DOI: 10.1111/j.1365-2567.2011.03408.x. View

Kurata S, Taguchi H, Sasaki T, Fujioka Y, Kamiya S . Antimicrobial and immunomodulatory effect of clarithromycin on macrolide-resistant Mycoplasma pneumoniae. J Med Microbiol. 2010; 59(Pt 6):693-701. DOI: 10.1099/jmm.0.014191-0. View

Yan Y, Wei Y, Jiang W, Hao C . The clinical characteristics of corticosteroid-resistant refractory Mycoplasma Pneumoniae pneumonia in children. Sci Rep. 2016; 6:39929. PMC: 5180238. DOI: 10.1038/srep39929. View

Guo H, He Z, Li M, Wang T, Zhang L . Imbalance of peripheral blood Th17 and Treg responses in children with refractory Mycoplasma pneumoniae pneumonia. J Infect Chemother. 2016; 22(3):162-6. DOI: 10.1016/j.jiac.2015.12.006. View

Zhang Y, Zhou Y, Li S, Yang D, Wu X, Chen Z . The Clinical Characteristics and Predictors of Refractory Mycoplasma pneumoniae Pneumonia in Children. PLoS One. 2016; 11(5):e0156465. PMC: 4882022. DOI: 10.1371/journal.pone.0156465. View

10.

. [Guidelines for management of community acquired pneumonia in children (the revised edition of 2013) (I)]. Zhonghua Er Ke Za Zhi. 2014; 51(10):745-52. View

11.

Shan L, Liu X, Kang X, Wang F, Han X, Shang Y . Effects of methylprednisolone or immunoglobulin when added to standard treatment with intravenous azithromycin for refractory Mycoplasma pneumoniae pneumonia in children. World J Pediatr. 2017; 13(4):321-327. DOI: 10.1007/s12519-017-0014-9. View

12.

Li S, Li X, Wang Y, Yang J, Chen Z, Shan S . Global secretome characterization of A549 human alveolar epithelial carcinoma cells during Mycoplasma pneumoniae infection. BMC Microbiol. 2014; 14:27. PMC: 3922035. DOI: 10.1186/1471-2180-14-27. View

13.

Chen L, Liu J, Zhao S, Yang Y, Wu J . [Clinical features and treatment of refractory Mycoplasma pneumoniae pneumonia unresponded to conventional dose methylprednisolone in children]. Zhonghua Er Ke Za Zhi. 2014; 52(3):172-6. View

14.

Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T . Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect. 2008; 57(3):223-8. PMC: 7112643. DOI: 10.1016/j.jinf.2008.06.012. View

15.

Lai J, Zindl C, Duffy L, Atkinson T, Jung Y, van Rooijen N . Critical role of macrophages and their activation via MyD88-NFκB signaling in lung innate immunity to Mycoplasma pneumoniae. PLoS One. 2011; 5(12):e14417. PMC: 3009709. DOI: 10.1371/journal.pone.0014417. View

16.

Chen Z, Shao X, Dou X, Zhang X, Wang Y, Zhu C . Role of the Mycoplasma pneumoniae/Interleukin-8/Neutrophil Axis in the Pathogenesis of Pneumonia. PLoS One. 2016; 11(1):e0146377. PMC: 4708980. DOI: 10.1371/journal.pone.0146377. View

17.

Craig A, Mai J, Cai S, Jeyaseelan S . Neutrophil recruitment to the lungs during bacterial pneumonia. Infect Immun. 2008; 77(2):568-75. PMC: 2632043. DOI: 10.1128/IAI.00832-08. View

18.

Foy H, Ochs H, Davis S, KENNY G, Luce R . Mycoplasma pneumoniae infections in patients with immunodeficiency syndromes: report of four cases. J Infect Dis. 1973; 127(4):388-93. DOI: 10.1093/infdis/127.4.388. View

19.

Brown I, Bellevue O, Shawo A, Woldesemayat H, Lyo V, Rayikanti B . Low-dose cyclophosphamide improves survival in a murine treatment model of sepsis. Shock. 2014; 43(1):92-8. PMC: 4269572. DOI: 10.1097/SHK.0000000000000263. View

20.

Xu X, Zhang D, Zhang H, Wolters P, Killeen N, Sullivan B . Neutrophil histamine contributes to inflammation in mycoplasma pneumonia. J Exp Med. 2006; 203(13):2907-17. PMC: 2118183. DOI: 10.1084/jem.20061232. View